REGISTRY PLATFORM INTO DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Non Small Cell Lung Cancer
- Sponsor
- Mahmut Gumus
- Enrollment
- 6000
- Locations
- 39
- Primary Endpoint
- Frequency of molecular/mutational analysis
- Status
- Active, Not Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
Detailed Description
In Turkey, non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in men and one of the most common causes of cancer-related deaths in women. Because of the heterogeneity of NSCLC or SCLC, it is crucial to characterize the biology of the tumor as exact as possible, to predict the course of disease as accurate as possible, and to determine the optimal therapeutic algorithm as early as possible after initial diagnostic work-up. These efforts are an obligatory part of the initial diagnostics, since thorough knowledge of the biology of the disease and the resulting therapeutic options ensure optimal care of Volunteers with NSCLC or SCLC. The aim of REGISTURK is to set up a national clinical research platform to document molecular testing, treatment and course of disease of patients with NSCLC or SCLC.
Investigators
Mahmut Gumus
Board Member of Oncological Clinical Research Association
Oncological Clinical Research Association, Turkey
Eligibility Criteria
Inclusion Criteria
- •Patient histopathologically diagnosed with non-small cell lung cancer or small cell lung cancer
- •Written informed consent no later than six weeks after start of first-line treatment
- •Age ≥ 18 years
Exclusion Criteria
- •Volunteers participating in a research program for non-small cell or small cell lung cancer that includes interventions outside of routine clinical trial
Outcomes
Primary Outcomes
Frequency of molecular/mutational analysis
Time Frame: throughout of treatment, 36 months
To collect data on the frequency of molecular/mutational biomarker testing
Type of molecular/mutational analysis
Time Frame: throughout of treatment, 36 months
To collect data on the type of molecular/mutational biomarker testing
Secondary Outcomes
- The Rate of Response Rate(throughout of treatment, 36 months)
- Type of treatment(throughout of treatment, 36 months)
- The frequency of comorbidities(throughout of treatment, 36 months)
- Advers events rate(throughout of treatment, 36 months)
- Progression free survival time(throughout of treatment, 36 months)
- Overall survival time(throughout of treatment, 36 months)